Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Advagene Biopharma Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions currently on record. These actions are assigned to 2 distinct examiners, providing the company with two different points of contact for its patent prosecution. The workload is further spread across 2 distinct art units, which suggests that the company's biopharmaceutical innovations fall into different technical classifications. This structure indicates that the company is pursuing multiple distinct avenues of protection within the biotechnology sector.
The busiest examiner for the portfolio is KINSEY WHITE, NICOLE ERIN, who is handling 1 busiest examiner pending office action. Given that there are 2 pending office actions in total, this examiner is responsible for a significant portion of the company's current active workload. This makes the relationship with KINSEY WHITE, NICOLE ERIN a major factor in the company's immediate success at the patent office. Practitioners should be prepared to manage two different examiner styles and two different sets of art unit guidelines. The results of the 2 pending office actions will be a key indicator of the company's ability to secure its pharmaceutical intellectual property across different specialized divisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| BELLECOURT, MICHAEL JOHN ALLEN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374118 | INTRANASAL VACCINE COMPOSITION AND METHOD FOR BOOSTING USING THE SAME | BELLECOURT, MICHAEL JOHN ALLEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18583389 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME | KINSEY WHITE, NICOLE ERIN | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18583389 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME | KINSEY WHITE, NICOLE ERIN | 1672 | §102DP | Non-Final OA | 31d overdue | Pending | Feb 21, 2024 |
| 18374118 | INTRANASAL VACCINE COMPOSITION AND METHOD FOR BOOSTING USING THE SAME | BELLECOURT, MICHAEL JOHN ALLEN | 1671 | §102§103§112Other | Non-Final OA | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdvagene Biopharma Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nicole Erin Kinsey White has the most, with 1 of Advagene Biopharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
